CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
Allogenic hematopoietic stem cell transplantation (allo-HSCT) is one of the standard treatments for B-cell lymphoproliferative disorders; however, deep relapses are common after an allo-HSCT, and it is associated with poor prognosis. A successful approach to overcome these relapses is to exploit the...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-09, Vol.13 (18), p.4664 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 18 |
| container_start_page | 4664 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Bartoló-Ibars, Ariadna Uribe-Herranz, Mireia Muñoz-Sánchez, Guillermo Arnaldos-Pérez, Cristina Ortiz-Maldonado, Valentín Urbano-Ispizua, Álvaro Pascal, Mariona Juan, Manel |
| description | Allogenic hematopoietic stem cell transplantation (allo-HSCT) is one of the standard treatments for B-cell lymphoproliferative disorders; however, deep relapses are common after an allo-HSCT, and it is associated with poor prognosis. A successful approach to overcome these relapses is to exploit the body's own immune system with chimeric antigen receptor (CAR) T-cells. These two approaches are potentially combinatorial for treating R/R B-cell lymphoproliferative disorders. Several clinical trials have described different scenarios in which allo-HSCT and CAR-T are successively combined. Further, for all transplanted patients, assessment of chimerism is important to evaluate the engraftment success. Nonetheless, for those patients who previously received an allo-HSCT there is no monitorization of chimerism before manufacturing CAR T-cells. In this review, we focus on allo-HSCT and CAR-T treatments and the different sources of T-cells for manufacturing CAR T-cells. |
| doi_str_mv | 10.3390/cancers13184664 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8470158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2577448485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-bdf13b033b33a105c601a903171d4e8494f54ae4eacb7c0a3a59ca88baa40843</originalsourceid><addsrcrecordid>eNpdkUFr3DAQhU1paUKac29F0EsvTiRLtuQeWtxt2gQWCqnvZqwdZxVkyZXswP6B_u5qk21IoosG3tPTfLwse8_oGec1PdfgNIbIOFOiqsSr7Ligssirqhavn8xH2WmMtzQdzpms5NvsiItSFqqmx9nfVXOdtwSGGQP5PeNIVmgtaQO4OFlwM8zGO2Ic-ZbfK-vdOG39FLw1A4ak3iH5bqIPm7TKZ9IEJO0Wd-QawdodaZbZW3_jl0h8II1NMzqjD79sU8JkMH59l70ZwEY8PdwnWfvjol1d5utfP69WzTrXopJz3m8GxvvE0XMOjJa6ogxqmrDYRqAStRhKASgQdC81BQ5lrUGpHkBQJfhJ9uUhdlr6ETca3RzAdlMwI4Rd58F0zxVntt2Nv-uUkJSVKgV8OgQE_2fBOHejiTqxgMPE2BWllEIoocpk_fjCeuuX4BLd3lVxVfBi7zp_cOngYww4PC7DaLdvuXvRcnrx4SnDo_9_p_wf_calzw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2576382325</pqid></control><display><type>article</type><title>CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Bartoló-Ibars, Ariadna ; Uribe-Herranz, Mireia ; Muñoz-Sánchez, Guillermo ; Arnaldos-Pérez, Cristina ; Ortiz-Maldonado, Valentín ; Urbano-Ispizua, Álvaro ; Pascal, Mariona ; Juan, Manel</creator><creatorcontrib>Bartoló-Ibars, Ariadna ; Uribe-Herranz, Mireia ; Muñoz-Sánchez, Guillermo ; Arnaldos-Pérez, Cristina ; Ortiz-Maldonado, Valentín ; Urbano-Ispizua, Álvaro ; Pascal, Mariona ; Juan, Manel</creatorcontrib><description>Allogenic hematopoietic stem cell transplantation (allo-HSCT) is one of the standard treatments for B-cell lymphoproliferative disorders; however, deep relapses are common after an allo-HSCT, and it is associated with poor prognosis. A successful approach to overcome these relapses is to exploit the body's own immune system with chimeric antigen receptor (CAR) T-cells. These two approaches are potentially combinatorial for treating R/R B-cell lymphoproliferative disorders. Several clinical trials have described different scenarios in which allo-HSCT and CAR-T are successively combined. Further, for all transplanted patients, assessment of chimerism is important to evaluate the engraftment success. Nonetheless, for those patients who previously received an allo-HSCT there is no monitorization of chimerism before manufacturing CAR T-cells. In this review, we focus on allo-HSCT and CAR-T treatments and the different sources of T-cells for manufacturing CAR T-cells.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13184664</identifier><identifier>PMID: 34572890</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Autografts ; Blood ; Bone marrow ; Cancer therapies ; Cell proliferation ; Cell survival ; Cell therapy ; Chemotherapy ; Chimeric antigen receptors ; Chimerism ; Clinical trials ; FDA approval ; Genes ; Graft versus host disease ; Hematology ; Hematopoietic stem cells ; Immune system ; Immunoproliferative diseases ; Immunotherapy ; Leukemia ; Lymphocytes ; Lymphocytes B ; Lymphocytes T ; Lymphoma ; Medical treatment ; Patients ; Review ; Stem cell transplantation ; Stem cells ; Transplants & implants</subject><ispartof>Cancers, 2021-09, Vol.13 (18), p.4664</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-bdf13b033b33a105c601a903171d4e8494f54ae4eacb7c0a3a59ca88baa40843</citedby><cites>FETCH-LOGICAL-c467t-bdf13b033b33a105c601a903171d4e8494f54ae4eacb7c0a3a59ca88baa40843</cites><orcidid>0000-0002-0308-6255 ; 0000-0002-7188-5411 ; 0000-0002-3064-1648</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470158/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470158/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34572890$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bartoló-Ibars, Ariadna</creatorcontrib><creatorcontrib>Uribe-Herranz, Mireia</creatorcontrib><creatorcontrib>Muñoz-Sánchez, Guillermo</creatorcontrib><creatorcontrib>Arnaldos-Pérez, Cristina</creatorcontrib><creatorcontrib>Ortiz-Maldonado, Valentín</creatorcontrib><creatorcontrib>Urbano-Ispizua, Álvaro</creatorcontrib><creatorcontrib>Pascal, Mariona</creatorcontrib><creatorcontrib>Juan, Manel</creatorcontrib><title>CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Allogenic hematopoietic stem cell transplantation (allo-HSCT) is one of the standard treatments for B-cell lymphoproliferative disorders; however, deep relapses are common after an allo-HSCT, and it is associated with poor prognosis. A successful approach to overcome these relapses is to exploit the body's own immune system with chimeric antigen receptor (CAR) T-cells. These two approaches are potentially combinatorial for treating R/R B-cell lymphoproliferative disorders. Several clinical trials have described different scenarios in which allo-HSCT and CAR-T are successively combined. Further, for all transplanted patients, assessment of chimerism is important to evaluate the engraftment success. Nonetheless, for those patients who previously received an allo-HSCT there is no monitorization of chimerism before manufacturing CAR T-cells. In this review, we focus on allo-HSCT and CAR-T treatments and the different sources of T-cells for manufacturing CAR T-cells.</description><subject>Antigens</subject><subject>Autografts</subject><subject>Blood</subject><subject>Bone marrow</subject><subject>Cancer therapies</subject><subject>Cell proliferation</subject><subject>Cell survival</subject><subject>Cell therapy</subject><subject>Chemotherapy</subject><subject>Chimeric antigen receptors</subject><subject>Chimerism</subject><subject>Clinical trials</subject><subject>FDA approval</subject><subject>Genes</subject><subject>Graft versus host disease</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>Immune system</subject><subject>Immunoproliferative diseases</subject><subject>Immunotherapy</subject><subject>Leukemia</subject><subject>Lymphocytes</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Medical treatment</subject><subject>Patients</subject><subject>Review</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transplants & implants</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUFr3DAQhU1paUKac29F0EsvTiRLtuQeWtxt2gQWCqnvZqwdZxVkyZXswP6B_u5qk21IoosG3tPTfLwse8_oGec1PdfgNIbIOFOiqsSr7Ligssirqhavn8xH2WmMtzQdzpms5NvsiItSFqqmx9nfVXOdtwSGGQP5PeNIVmgtaQO4OFlwM8zGO2Ic-ZbfK-vdOG39FLw1A4ak3iH5bqIPm7TKZ9IEJO0Wd-QawdodaZbZW3_jl0h8II1NMzqjD79sU8JkMH59l70ZwEY8PdwnWfvjol1d5utfP69WzTrXopJz3m8GxvvE0XMOjJa6ogxqmrDYRqAStRhKASgQdC81BQ5lrUGpHkBQJfhJ9uUhdlr6ETca3RzAdlMwI4Rd58F0zxVntt2Nv-uUkJSVKgV8OgQE_2fBOHejiTqxgMPE2BWllEIoocpk_fjCeuuX4BLd3lVxVfBi7zp_cOngYww4PC7DaLdvuXvRcnrx4SnDo_9_p_wf_calzw</recordid><startdate>20210917</startdate><enddate>20210917</enddate><creator>Bartoló-Ibars, Ariadna</creator><creator>Uribe-Herranz, Mireia</creator><creator>Muñoz-Sánchez, Guillermo</creator><creator>Arnaldos-Pérez, Cristina</creator><creator>Ortiz-Maldonado, Valentín</creator><creator>Urbano-Ispizua, Álvaro</creator><creator>Pascal, Mariona</creator><creator>Juan, Manel</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0308-6255</orcidid><orcidid>https://orcid.org/0000-0002-7188-5411</orcidid><orcidid>https://orcid.org/0000-0002-3064-1648</orcidid></search><sort><creationdate>20210917</creationdate><title>CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?</title><author>Bartoló-Ibars, Ariadna ; Uribe-Herranz, Mireia ; Muñoz-Sánchez, Guillermo ; Arnaldos-Pérez, Cristina ; Ortiz-Maldonado, Valentín ; Urbano-Ispizua, Álvaro ; Pascal, Mariona ; Juan, Manel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-bdf13b033b33a105c601a903171d4e8494f54ae4eacb7c0a3a59ca88baa40843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Autografts</topic><topic>Blood</topic><topic>Bone marrow</topic><topic>Cancer therapies</topic><topic>Cell proliferation</topic><topic>Cell survival</topic><topic>Cell therapy</topic><topic>Chemotherapy</topic><topic>Chimeric antigen receptors</topic><topic>Chimerism</topic><topic>Clinical trials</topic><topic>FDA approval</topic><topic>Genes</topic><topic>Graft versus host disease</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>Immune system</topic><topic>Immunoproliferative diseases</topic><topic>Immunotherapy</topic><topic>Leukemia</topic><topic>Lymphocytes</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Medical treatment</topic><topic>Patients</topic><topic>Review</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bartoló-Ibars, Ariadna</creatorcontrib><creatorcontrib>Uribe-Herranz, Mireia</creatorcontrib><creatorcontrib>Muñoz-Sánchez, Guillermo</creatorcontrib><creatorcontrib>Arnaldos-Pérez, Cristina</creatorcontrib><creatorcontrib>Ortiz-Maldonado, Valentín</creatorcontrib><creatorcontrib>Urbano-Ispizua, Álvaro</creatorcontrib><creatorcontrib>Pascal, Mariona</creatorcontrib><creatorcontrib>Juan, Manel</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bartoló-Ibars, Ariadna</au><au>Uribe-Herranz, Mireia</au><au>Muñoz-Sánchez, Guillermo</au><au>Arnaldos-Pérez, Cristina</au><au>Ortiz-Maldonado, Valentín</au><au>Urbano-Ispizua, Álvaro</au><au>Pascal, Mariona</au><au>Juan, Manel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2021-09-17</date><risdate>2021</risdate><volume>13</volume><issue>18</issue><spage>4664</spage><pages>4664-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Allogenic hematopoietic stem cell transplantation (allo-HSCT) is one of the standard treatments for B-cell lymphoproliferative disorders; however, deep relapses are common after an allo-HSCT, and it is associated with poor prognosis. A successful approach to overcome these relapses is to exploit the body's own immune system with chimeric antigen receptor (CAR) T-cells. These two approaches are potentially combinatorial for treating R/R B-cell lymphoproliferative disorders. Several clinical trials have described different scenarios in which allo-HSCT and CAR-T are successively combined. Further, for all transplanted patients, assessment of chimerism is important to evaluate the engraftment success. Nonetheless, for those patients who previously received an allo-HSCT there is no monitorization of chimerism before manufacturing CAR T-cells. In this review, we focus on allo-HSCT and CAR-T treatments and the different sources of T-cells for manufacturing CAR T-cells.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34572890</pmid><doi>10.3390/cancers13184664</doi><orcidid>https://orcid.org/0000-0002-0308-6255</orcidid><orcidid>https://orcid.org/0000-0002-7188-5411</orcidid><orcidid>https://orcid.org/0000-0002-3064-1648</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-09, Vol.13 (18), p.4664 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8470158 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antigens Autografts Blood Bone marrow Cancer therapies Cell proliferation Cell survival Cell therapy Chemotherapy Chimeric antigen receptors Chimerism Clinical trials FDA approval Genes Graft versus host disease Hematology Hematopoietic stem cells Immune system Immunoproliferative diseases Immunotherapy Leukemia Lymphocytes Lymphocytes B Lymphocytes T Lymphoma Medical treatment Patients Review Stem cell transplantation Stem cells Transplants & implants |
| title | CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A52%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CAR-T%20after%20Stem%20Cell%20Transplantation%20in%20B-Cell%20Lymphoproliferative%20Disorders:%20Are%20They%20Really%20Autologous%20or%20Allogenic%20Cell%20Therapies?&rft.jtitle=Cancers&rft.au=Bartol%C3%B3-Ibars,%20Ariadna&rft.date=2021-09-17&rft.volume=13&rft.issue=18&rft.spage=4664&rft.pages=4664-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13184664&rft_dat=%3Cproquest_pubme%3E2577448485%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2576382325&rft_id=info:pmid/34572890&rfr_iscdi=true |